Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467144 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL3301916 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL3302759 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL3305912 | 0.82 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL858141 | 0.81 | KDM4E (0.65) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL8169222 | 0.81 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL5683830 | 0.81 | KDM4E (0.59) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL8165752 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10LMNAPOLB | |
| SCHEMBL3307771 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10LMNASMN1; SMN2 | |
| SCHEMBL3302729 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114951-B9 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2015-09-02 | — | — | EP | disclosed |
| EP-2114951-B9 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2015-09-02 | — | — | EP | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-8338431-B2 | Phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2012-12-25 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2010-04-22 | — | — | US | disclosed |
| EP-2114951-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104175-A2 | NOVEL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099688-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE5A, PDE3B | KDM4E 1235/4885ALDH1A1 372/4885HSD17B10 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.